Business Wire

Novaliq Announces First Patient Randomized in Its ESSENCE Phase 2b/3 Trial of CyclASol® for the Treatment of the Signs and Symptoms of Dry Eye Disease

Del

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that it has begun randomization of patients in its ESSENCE Phase 2b/3 clinical trial that will evaluate CyclASol® for the treatment of the signs and symptoms of dry eye disease (DED).

DED is a multifactorial and complex disease of the ocular surface. Ocular surface inflammation and autoimmune dysregulation play a key etiological role in the development of DED. In the U.S. alone, an estimated >16 million people suffer from DED1. This patient population is highly underserved as there are only a few approved drugs in select key markets.

CyclASol® is a preservative free ophthalmic solution of cyclosporine A in EyeSol®, Novaliq’s proprietary and first and only water-free technology. Excellent safety and tolerability of CyclASol® as well as the ability to improve signs and symptoms of DED with an early onset of effect have been demonstrated in a previous Phase 2 study. The results of this Phase 2 study are being presented [PO059] at AAO 2017, the American Academy of Ophthalmology’s 121st annual meeting, which takes place November 11-14, 2017 in New Orleans. CyclASol® potentially overcomes the current intolerability and efficacy profiles due to the benefits of a water-free vehicle and the mechanism of drug delivery.

“Medications with highly favorable tolerability profiles and early onset of action are an unmet medical need in dry eye disease,” said John Sheppard MD, Professor of Ophthalmology, Eastern Virginia Medical School. “Based on the very promising data from the CyclASol® Phase 2 study, we are excited to participate in the ESSENCE trial, thereby moving this promising product closer to the market.”

Novaliq’s ESSENCE 2b/3 clinical trial (NCT03292809) is a randomized, double-masked, vehicle-controlled, multi-center trial, designed to evaluate the safety, efficacy and tolerability of topical CyclASol® for the treatment of DED. Study patients will be randomized to one of two treatment groups: CyclASol® and vehicle. ESSENCE has a primary efficacy endpoint at 4 weeks with continued dosing for safety evaluation over a total of 3 months. The study is being conducted in approximately 10 sites in the U.S., with a total planned enrollment of approximately 316 patients.

“The initiation of this phase 2b/3 trial of the CyclASol® program is a major milestone in advancing our clinical development of CyclASol®,” says Sonja Krösser, PhD, VP Clinical Development at Novaliq GmbH. “This pivotal trial design has been based on sound prior data demonstrating superior reduction of corneal and conjunctival staining as well as OSDI© of CyclASol® over its vehicle in the population selected for ESSENCE. This trial is designed to support planned regulatory applications worldwide, including the United States, Europe and Japan."

About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. Novaliq’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.

Source:
1. K.F. Farrand et al.: Am J Ophthalmol. 2017 Oct;182:90-98

Contact information

Novaliq GmbH
For US:
Michael O’Rourke, + 1 813 323 1438
Strategic Consultant, ext.
mrourke@novaliq.com
or
For EU/Asia:
Heidrun Kirsch + 49 6221 50259 243
VP Marketing
hkirsch@novaliq.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Schlumberger Announces Third-Quarter 2018 Results Conference Call21.8.2018 17:05Pressemelding

Schlumberger Limited (NYSE:SLB) will hold a conference call on October 19, 2018 to discuss the results for the third quarter ending September 30, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 19, 2018, and can be accessed by dialing +1 (800) 475-6701 withi

Amazon Game Studios Announces The Grand Tour Game21.8.2018 15:00Pressemelding

Amazon.com (NASDAQ: AMZN) today announced that Jeremy Clarkson, Richard Hammond, and James May are bringing high-jinks and hot laps to PlayStation 4 and Xbox One in The Grand Tour Game, an episodic racing game based on the hit Prime Original series, The Grand Tour. Created by Amazon Game Studios, The Grand Tour Game transports players to exotic locations, where they'll drive the world's most interesting cars, and participate in the show's outrageous challenges. New episodes of The Grand Tour Game will be added weekly during Season 3 of the show, capturing cars, locations, and surprises from each week's episode. Visit www.playthegrandtourgame.com for more information. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180821005353/en/ The Grand Tour Game puts players behind the wheel of the cars from Season 3, and brings them to the iconic locations the hosts will visit this season, including The Grand Tour's signature Eboladrome

Andersen Global Expands in Africa with Oliveira & Associados21.8.2018 13:30Pressemelding

Andersen Global continues its expansion in Africa through a Collaboration Agreement with Oliveira & Associados, a law firm based in Angola, founded by Formosa Oliveira in 2016. Andersen Global Chairman and Andersen Tax LLC CEO, Mark Vorsatz, commented, “The economy in Angola is one of the fastest growing in the world, and we are excited about adding this practice in a market that has a strong connection to Portugal and is strategic to our business in Portugal. Oliveira & Associados is an energetic and talented group, and with the addition of Isalcio Mahanjane e Associados in Mozambique last week, we have added key locations in our Portuguese and Iberian strategy.” With headquarters in Luanda, Oliveira & Associados provides legal services to both corporate and individual clients within Africa and globally. “Collaborating with Andersen Global will help us extend our reach as we develop and seamlessly deliver cross-border solutions,” remarked Formosa Oliveira. “With added tax and legal se

Mavenir Introduces RCS Business Messaging Partner Program to Enable MNO’s A2P Revenue Growth21.8.2018 13:00Pressemelding

Mavenir, the world’s #1 messaging systems provider and a leader in Rich Communication Services (RCS)—with an 85% market share in North America—today announced its RCS Business Messaging Partner Program with 15 confirmed partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180821005089/en/ Mavenir’s RBM Chatbot (Photo: Business Wire) The Mavenir RCS Business Messaging (RBM) solution enables brands, aggregators, content providers, enterprises and MNOs to monetize RCS messaging technologies and provide rich, multimedia end-user experiences from the native messaging application on mobile devices. This global partner program is focused on accelerating the adoption of RCS multimedia messaging by creating a community of industry leading messaging partners to provide MNOs with a compelling business-to-consumer (B2C) messaging channel and become the platform of choice for advertisers, brands, content providers and enterprises to

Dynacor Announces First Quarterly Dividend Payment21.8.2018 12:03Pressemelding

Dynacor Gold Mines Inc. (TSX: DNG) (OTC: DNGDF) (Dynacor or the Corporation) is pleased to announce today that its Board of Directors (Board) has approved the initiation of quarterly cash dividends to its shareholders and the declaration of the first cash dividend in the company's history. The dividend of CAD$ 0.01 per common share, is payable on October 1, 2018 to shareholders of record on September 20, 2018. Dynacor is one of the largest ore purchasing processors in Peru. With its new ore processing facility operating at near full capacity, the Corporation is forecasting 2018 to be its best year on record. Dynacor’s stable business model is proven to withstand the volatility of the gold price. The Corporation is free of debt, in a healthy financial situation and working towards its 30th consecutive quarter of profits. President and CEO Jean Martineau states, “Our team has worked very hard to build the Corporation to what it is today. Our solid financial situation and leadership posit

FAA Approves AerTrak for Boeing 757-200 Series Aircraft to Comply with Automatic Dependent Surveillance-Broadcast (ADS-B) Operations Mandate21.8.2018 12:00Pressemelding

The Federal Aviation Administration (FAA) has issued a Supplemental Type Certificate (STC) for installation of AerSale®’s AerTrak™ system on Boeing 757-200 series aircraft (ST04011NY), to comply with the Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule, a critical part of the agency’s Next Generation Air Transportation System (NextGen). Beginning January 1, 2020, the FAA has mandated that aircraft operating in airspace defined by 14 CFR § 91.225 must be equipped with an ADS-B Out system that meets the minimum performance requirements of 14 CFR § 91.227. The FAA approved AerTrak for Boeing 737 NG series aircraft (ST04009NY) earlier this year. ADS-B provides enhanced navigational accuracy using precise tracking via global positioning satellite (GPS) signals. Reducing risk and improving safety, the technology increases navigational coverage, especially in remote areas beyond radar range. Additionally, ADS-B enables more direct flight plans, thereby saving time, costs, an